AVIR
NASDAQ · Pharmaceuticals
Atea Pharmaceuticals Inc
$5.39
+0.06 (+1.13%)
Financial Highlights (FY 2025)
Revenue
49.99M
Net Income
8.60M
Gross Margin
57.3%
Profit Margin
17.2%
Rev Growth
+19.5%
D/E Ratio
0.36
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 57.3% | 57.3% | 57.3% |
| Operating Margin | 23.1% | 22.2% | 20.8% |
| Profit Margin | 17.2% | 23.3% | 16.7% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 49.99M | 49.26M | 44.69M |
| Gross Profit | 28.64M | 28.22M | 25.60M |
| Operating Income | 11.56M | 10.94M | 9.30M |
| Net Income | 8.60M | 11.50M | 7.45M |
| Gross Margin | 57.3% | 57.3% | 57.3% |
| Operating Margin | 23.1% | 22.2% | 20.8% |
| Profit Margin | 17.2% | 23.3% | 16.7% |
| Rev Growth | +19.5% | +7.9% | +2.0% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 64.88M | 64.62M | 54.80M |
| Total Equity | 181.02M | 180.81M | 173.08M |
| D/E Ratio | 0.36 | 0.36 | 0.32 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 12.90M | 12.92M | 13.20M |
| Free Cash Flow | 9.03M | 8.66M | 6.93M |